The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Silvadene     4-amino-N-pyrimidin-2-yl- benzenesulfonamide

Synonyms: Adiazine, Diazovit, Sulfazine, Thermazene, sulfadiazine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sulfadiazine


High impact information on sulfadiazine


Chemical compound and disease context of sulfadiazine


Biological context of sulfadiazine


Anatomical context of sulfadiazine


Associations of sulfadiazine with other chemical compounds


Gene context of sulfadiazine


Analytical, diagnostic and therapeutic context of sulfadiazine


  1. Leukopenia secondary to sulfadiazine silver. Fraser, G.L., Beaulieu, J.T. JAMA (1979) [Pubmed]
  2. Argyria from excessive use of topical silver sulphadiazine. Payne, C.M., Bladin, C., Colchester, A.C., Bland, J., Lapworth, R., Lane, D. Lancet (1992) [Pubmed]
  3. Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure. Goadsby, P.J., Donaghy, A.J., Lloyd, A.R., Wakefield, D. Ann. Intern. Med. (1987) [Pubmed]
  4. Role of clindamycin in the treatment of central nervous system toxoplasmosis. Rolston, K.V., Hoy, J. Am. J. Med. (1987) [Pubmed]
  5. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. Molina, J.M., Belenfant, X., Doco-Lecompte, T., Idatte, J.M., Modai, J. AIDS (1991) [Pubmed]
  6. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. Ann. Intern. Med. (1997) [Pubmed]
  7. Pyrimethamine, sulfadiazine, and villous atrophy of the jejunum. Puckett, J.B., Cooper, M.R., Stuart, J.J., Wu, W.C., Sterchi, J.M. Ann. Intern. Med. (1982) [Pubmed]
  8. Intracranial infection in cardiac transplant recipients. Britt, R.H., Enzmann, D.R., Remington, J.S. Ann. Neurol. (1981) [Pubmed]
  9. Depletion of CD4+ T cells but not inhibition of the protective activity of IFN-gamma prevents cure of toxoplasmosis mediated by drug therapy in mice. Araujo, F.G. J. Immunol. (1992) [Pubmed]
  10. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Katlama, C., Mouthon, B., Gourdon, D., Lapierre, D., Rousseau, F. AIDS (1996) [Pubmed]
  11. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Leport, C., Raffi, F., Matheron, S., Katlama, C., Regnier, B., Saimot, A.G., Marche, C., Vedrenne, C., Vilde, J.L. Am. J. Med. (1988) [Pubmed]
  12. Active drug metabolites and renal failure. Drayer, D.E. Am. J. Med. (1977) [Pubmed]
  13. Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Erill, S., Calvo, R., Carlos, R. Clin. Pharmacol. Ther. (1980) [Pubmed]
  14. Management of drug allergy in patients with acquired immunodeficiency syndrome. Greenberger, P.A., Patterson, R. J. Allergy Clin. Immunol. (1987) [Pubmed]
  15. Between a rock and a hard place: disclosing medical errors. Crone, K.G., Muraski, M.B., Skeel, J.D., Love-Gregory, L., Ladenson, J.H., Gronowski, A.M. Clin. Chem. (2006) [Pubmed]
  16. Kinetics of a sulfadiazine-trimethoprim combination. Bergan, T., Vik-Mo, H., Anstad, U. Clin. Pharmacol. Ther. (1977) [Pubmed]
  17. Plasmids coding for drug resistance and localized adherence to HeLa cells in enteropathogenic Escherichia coli O55:H- and O55:H6. Laporta, M.Z., Silva, M.L., Scaletsky, I.C., Trabulsi, L.R. Infect. Immun. (1986) [Pubmed]
  18. Sulfadiazine handling in the rabbit. II. Mechanisms of nonlinear kinetics of elimination. du Souich, P., McLean, A.J., Lalka, D., Vicuna, N., Chauhuri, E., McNay, J.L. J. Pharmacol. Exp. Ther. (1978) [Pubmed]
  19. Concentrations of sulphadiazine and trimethoprim in nasal secretion after co-trimazine administration. Ullmann, U., Giebel, W., Bamberg, P. J. Antimicrob. Chemother. (1983) [Pubmed]
  20. Immunosuppression and toxoplasmic encephalitis: clinical and experimental aspects. Frenkel, J.K., Nelson, B.M., Arias-Stella, J. Hum. Pathol. (1975) [Pubmed]
  21. Gamma interferon production, but not perforin-mediated cytolytic activity, of T cells is required for prevention of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease. Wang, X., Kang, H., Kikuchi, T., Suzuki, Y. Infect. Immun. (2004) [Pubmed]
  22. Fungicidal activity of rabbit alveolar and peritoneal macrophages against Candida albicans. Lehrer, R.I., Ferrari, L.G., Patterson-Delafield, J., Sorrell, T. Infect. Immun. (1980) [Pubmed]
  23. In vitro assessment of antimicrobial agents against Toxoplasma gondii. Harris, C., Salgo, M.P., Tanowitz, H.B., Wittner, M. J. Infect. Dis. (1988) [Pubmed]
  24. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii. Khan, A.A., Lambert, L.H., Remington, J.S., Araujo, F.G. Antimicrob. Agents Chemother. (1999) [Pubmed]
  25. A short-term study of tetroxoprim/sulphadiazine in the treatment of acute bronchitis and urinary tract infections. Ferber, H., Ahrens, K.H., Haase, W. J. Antimicrob. Chemother. (1979) [Pubmed]
  26. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Derouin, F., Almadany, R., Chau, F., Rouveix, B., Pocidalo, J.J. Antimicrob. Agents Chemother. (1992) [Pubmed]
  27. Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice. Sarciron, M.E., Lawton, P., Saccharin, C., Petavy, A.F., Peyron, F. Antimicrob. Agents Chemother. (1997) [Pubmed]
  28. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Walzer, P.D., Kim, C.K., Foy, J.M., Linke, M.J., Cushion, M.T. Antimicrob. Agents Chemother. (1988) [Pubmed]
  29. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Henry, K.W., Cruz, M.C., Katiyar, S.K., Edlind, T.D. Antimicrob. Agents Chemother. (1999) [Pubmed]
  30. Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion. Männistö, P.T., Mäntylä, R., Mattila, J., Nykänen, S., Lamminsivu, U. J. Antimicrob. Chemother. (1982) [Pubmed]
  31. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Winter, H.R., Unadkat, J.D. Drug Metab. Dispos. (2005) [Pubmed]
  32. Induction of tumor necrosis factor-alpha and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-gamma in genetically resistant BALB/c mice. Suzuki, Y., Kang, H., Parmley, S., Lim, S., Park, D. Microbes Infect. (2000) [Pubmed]
  33. IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii. Wille, U., Nishi, M., Lieberman, L., Wilson, E.H., Roos, D.S., Hunter, C.A. Parasite Immunol. (2004) [Pubmed]
  34. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. Araujo, F.G., Khan, A.A., Bryskier, A., Remington, J.S. J. Antimicrob. Chemother. (1998) [Pubmed]
  35. Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. Tenant-Flowers, M., Boyle, M.J., Carey, D., Marriott, D.J., Harkness, J.L., Penny, R., Cooper, D.A. AIDS (1991) [Pubmed]
  36. Alteration of plasma albumin in relation to decreased drug binding in uremia. Boobis, S.W. Clin. Pharmacol. Ther. (1977) [Pubmed]
  37. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Piketty, C., Derouin, F., Rouveix, B., Pocidalo, J.J. Antimicrob. Agents Chemother. (1990) [Pubmed]
  38. In vitro susceptibility testing of Paracoccidioides brasiliensis to sulfonamides. Restrepo, A., Arango, M.D. Antimicrob. Agents Chemother. (1980) [Pubmed]
WikiGenes - Universities